These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 8531895)

  • 21. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency.
    Gonc EN; Kandemir N
    Clin Endocrinol (Oxf); 2007 May; 66(5):672-7. PubMed ID: 17381489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum markers of bone metabolism in dogs.
    Allen MJ; Hoffmann WE; Richardson DC; Breur GJ
    Am J Vet Res; 1998 Mar; 59(3):250-4. PubMed ID: 9522938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone mineral density in patients with growth hormone deficiency: does a gender difference exist?
    Hitz MF; Jensen JE; Eskildsen PC
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):783-91. PubMed ID: 17121531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y; Ochi M; Tokue A
    Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of 12-month GH treatment on bone metabolism and bone mineral density in adults with adult-onset GH deficiency.
    Sartorio A; Ortolani S; Galbiati E; Conte G; Vangeli V; Arosio M; Porretti S; Faglia G
    J Endocrinol Invest; 2001 Apr; 24(4):224-30. PubMed ID: 11383908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
    Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y
    Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone turnover responses to changed physical activity.
    Karlsson KM; Karlsson C; Ahlborg HG; Valdimarsson O; Ljunghall S; Obrant KJ
    Calcif Tissue Int; 2003 Jun; 72(6):675-80. PubMed ID: 14562995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum bone GLA-protein in growth hormone deficient children.
    Delmas PD; Chatelain P; Malaval L; Bonne G
    J Bone Miner Res; 1986 Aug; 1(4):333-8. PubMed ID: 3509741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
    Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
    J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Serum levels of the carboxyterminal telopeptide of type I collagen in patients with thyroid disorders].
    Conti A; Monzani M; Persani L; Sartorio A
    Minerva Endocrinol; 1994 Sep; 19(3):127-31. PubMed ID: 7799894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group.
    Longobardi S; Keay N; Ehrnborg C; Cittadini A; Rosén T; Dall R; Boroujerdi MA; Bassett EE; Healy ML; Pentecost C; Wallace JD; Powrie J; Jørgensen JO; Saccà L
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1505-12. PubMed ID: 10770189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The duration of exercise as a regulator of bone turnover.
    Karlsson KM; Karlsson C; Ahlborg HG; Valdimarsson O; Ljunghall S
    Calcif Tissue Int; 2003 Oct; 73(4):350-5. PubMed ID: 12874708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Biochemical markers of bone formation activity in children with neoplasms].
    Muszyńska-Rosłan K; Krawczuk-Rybak M; Protas P; Siedlecka E; Wiśniewska M; Wołczyński S
    Wiad Lek; 2005; 58(1-2):29-35. PubMed ID: 15991550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia.
    Crofton PM; Ahmed SF; Wade JC; Stephen R; Elmlinger MW; Ranke MB; Kelnar CJ; Wallace WH
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3121-9. PubMed ID: 9745414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined evaluation of resting IGF-I, N-terminal propeptide of type III procollagen (PIIINP) and C-terminal cross-linked telopeptide of type I collagen (ICTP) levels might be useful for detecting inappropriate GH administration in athletes: a preliminary report.
    Sartorio A; Agosti F; Marazzi N; Maffiuletti NA; Cella SG; Rigamonti AE; Guidetti L; Di Luigi L; Muller EE
    Clin Endocrinol (Oxf); 2004 Oct; 61(4):487-93. PubMed ID: 15473882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children with growth hormone (GH) deficiency during GH therapy.
    Kubo T; Tanaka H; Inoue M; Kanzaki S; Seino Y
    Bone; 1995 Oct; 17(4):397-401. PubMed ID: 8573414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome.
    Klinger B; Jensen LT; Silbergeld A; Laron Z
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):423-9. PubMed ID: 8959080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Currently used growth-promoting treatment of children results in normal bone mass and density. A prospective trial of discontinuing growth hormone treatment in adolescents.
    Fors H; Bjarnason R; Wirént L; Albertsson-Wikland K; Bosaeust L; Bengtsson BA; Johannsson G
    Clin Endocrinol (Oxf); 2001 Nov; 55(5):617-24. PubMed ID: 11894973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.